AB3A Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Sarepta Therapeutics Inc

Watchlist Manager

Watchlist

Price: 17.61 EUR -2.06%

Market Cap: €1.1B

S	Sarepta Therapeutics Inc XMUN:AB3A	US
	Golden Minerals Co TSX:AUMN	US
S	Sparekassen Sjaelland-Fyn A/S F:4AC	DK
C	clearvise AG DUS:ABO	DE
	Nippon Prologis REIT Inc F:9NPA	JP

Profitability Summary

Sarepta Therapeutics Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

69%

Strong 3Y Average Gross Margin

83%

Declining Gross Margin

85% > 69%

Negative Operating Margin

-22%

Negative 3Y Average Operating Margin

-16%

Operating Margin is Increasing

-60% > -22%

Negative Net Margin

-32%

Negative 3Y Average Net Margin

-29%

Net Margin is Increasing

-114% > -32%

Negative Free Cash Flow Margin

-14%

Negative 3Y Average Free Cash Flow Margin

-35%

Free Cash Flow Margin is Increasing

-48% > -14%

Negative ROE

-53%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-16%

ROIC is Increasing

-58% > -22%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

69%

Strong 3Y Average Gross Margin

83%

Declining Gross Margin

85% > 69%

Negative Operating Margin

-22%

Negative 3Y Average Operating Margin

-16%

Operating Margin is Increasing

-60% > -22%